Abstract. Complement receptor 1-related gene/protein y (Crry) in rodents is a potent membrane complement regulator that inhibits complement C3 activation by both classical and alternative pathways. Complement inhibition with Crry as the recombinant protein Crry-Ig has been demonstrated to prevent MRL/MpJ-Tnfrsf6 lpr (MRL/lpr) mice from developing proteinuria and renal failure. Crry-Ig-treated mice also showed less glomerulosclerosis compared with control MRL/lpr mice. To clarify how complement inhibition with Crry might affect renal scarring in lupus nephritis, gene transcript profiling was performed comparing Crry-Ig-treated MRL/lpr mice to controltreated MRL/lpr mice as well as to the MRL/ϩ strain control. Altered gene expression was confirmed by quantitative PCR, and protein quantity with either immunoblotting or immunofluorescence microscopy. Collagens I, III, IV, and VI were overexpressed in control MRL/lpr mice, whereas complement inhibition with Crry reduced the overexpression of these extracellular matrix components toward normal. Plasminogen activator inhibitor 1, connective tissue growth factor, and TGF-1 were upregulated in MRL/lpr mice compared with MRL/ϩ mice and were normalized by Crry-Ig treatment, suggesting that the product of these genes may contribute to the progressive glomerulosclerosis in MRL/lpr mice in a complement-dependent fashion. Thus, complement inhibition with Crry has a prominent effect on matrix-related genes and proteins, which translates into improvement in functional renal disease.The MRL/MpJ-Tnfrsf6 lpr (MRL/lpr) strain is a murine model of human systemic lupus erythematosus. These mice develop many features of human systemic lupus erythematosus, including autoantibodies, hypocomplementemia, and proliferative glomerulonephritis (GN) (1,2). MRL/lpr mice differ from the lupus-prone congenic MRL/ϩ strain by the nearly complete absence of the apoptosis-promoting membrane Fas protein, which is due to a retroviral insertion in the Tnfrsf6 (Fas) gene (3,4). In contrast to MRL/lpr mice, MRL/ϩ mice develop lupus very late in life, including only mild renal disease. Renal disease in MRL/lpr mice has similar features to the human disease it models, with mesangial proliferative GN early in disease and diffuse proliferative and crescentic GN later in the course. Ultimately, glomerulosclerosis and renal failure occur in the terminal phase of disease and are believed to cause death in these mice (5). Decreased serum C3 levels and deposition of C3 activation fragments and other complement components in kidney suggest that complement is involved in the pathogenesis of murine as well as human lupus nephritis (2).Complement activation can proceed via the classical, alternative, or mannose-binding lectin pathways (6). Activation through each of the three pathways leads to cleavage of C3 with generation of the proinflammatory and regulatory fragments C3a and C3b. C3b attaches covalently to immune complexes, which is followed by C5 binding and its cleavage to C5a and C5b. The former is a potent in...